1d
GlobalData on MSNOno’s TGCT therapy wins FDA approval, challenging Daiichi SankyoOno Pharmaceutical has secured approval from the US Food and Drug Administration (FDA) for its kinase inhibitor Romvimza ...
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...
Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral ...
Ono – which acquired rights to Romvimza when it bought Deciphera Pharma in a $2.4 billion deal that closed in 2023 – said ...
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
Northern TK Venture filed a claim against Daiichi Sankyo saying the latter prevented NTK from proceeding with its open offer.
Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao ...
IHH’s subsidiary Northern TK Venture (NTK) had filed a claim against Daiichi Sankyo saying the latter prevented NTK from ...
Delhi: IHH Healthcare, a prominent global healthcare provider, has escalated its legal battle with Japan's Daiichi Sankyo, ...
The tussle between IHH Healthcare Bhd, Asia’s biggest private healthcare provider, and Daiichi Sankyo Co Ltd, a ...
Northern TK Venture Pte Ltd, IHH Healthcare's Singaporean arm, has raised its claim against Daiichi Sankyo in Tokyo for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results